Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Declines By 39.2%

Posted by Tyrone Williams on Mar 17th, 2025

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 955,300 shares, a decline of 39.2% from the February 13th total of 1,570,000 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily volume of 5,260,000 shares, the short-interest ratio is currently 0.2 days.

Virpax Pharmaceuticals Stock Performance

Shares of VRPX opened at $0.17 on Monday. The company’s fifty day moving average is $0.28 and its 200 day moving average is $0.48. Virpax Pharmaceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $4.83.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. 32.23% of the stock is owned by hedge funds and other institutional investors.

Virpax Pharmaceuticals Company Profile

(Get Free Report)

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.